The More Life Company Advancing U.S. Compounded Pharmaceutical Commercialization Pathway for Quicksome™
The More Life Company (CSE: MLCO, OTC: TMLCF) signed a letter of intent with an established U.S. 503A compounding pharmacy to develop and commercialize Quicksome™-enabled prescription compounded products in the United States. The LOI is non-binding except for customary provisions, and the partner is not being publicly identified at this stage. Initial applications under evaluation include hormone replacement, peptides and other active compounds.
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.